OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis and other cardiometabolic indications. OliX will receive an initial payment from Lilly to complete the Phase 1 clinical trial, currently underway in Australia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Hims & Hers jumps ahead of controversial Super Bowl ad airing
- Trump Trade: President advocates to close carried interest tax loophole
- Eli Lilly price target raised to $1,000 from $997 at BofA
- Viking Therapeutics price target lowered to $70 from $120 at Maxim
- Eli Lilly & Co: Buy Rating Affirmed on Strong Pipeline and Strategic Growth Initiatives